(Q37550846)

English

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

scientific article published on 20 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

phase III clinical trial

0 references

0 references

randomized experiment

1 reference

based on heuristic

inferred from title

zoledronic acid

1 reference

based on heuristic

inferred from title

S. Vincent Rajkumar

14

object named as

S V Rajkumar

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

10

object named as

M A Gertz

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

9

object named as

J A Lust

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

3

object named as

M Q Lacy

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Angela Dispenzieri

5

object named as

A Dispenzieri

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

author name string

T E Witzig

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

K M Laumann

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

S R Hayman

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

S Kumar

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

C B Reeder

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

V Roy

8

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

P R Greipp

11

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

H Hassoun

12

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

S J Mandrekar

13

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

publication date

20 August 2012

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

220-225

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

randomized experiment

0 references

https://scigraph.springernature.com/pub.10.1038/leu.2012.236

0 references

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

Prevalence of monoclonal gammopathy of undetermined significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

23 August 2017

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

6 September 2017

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

14 September 2017

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

25 June 2018

Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

25 June 2018

Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

25 June 2018

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

1 September 2018

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3912579

1 September 2018

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.236

21 January 2018

Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22902362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22902362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22902362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/22902362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22902362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinically relevant end points and new drug approvals for myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22902362

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2012.236

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37550846&oldid=2154671652"